Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1500-1503

  Azor, Mónica ^a   Gené, Josepa ^a   Cano, Josep ^a   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FUNGAL GENETICS; FUNGAL STRAIN; FUSARIUM SOLANI; IN VITRO STUDY; MULTILOCUS SEQUENCE TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; UNINDEXED SEQUENCE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; FUSARIUM; MICROBIAL SENSITIVITY TESTS; PHYLOGENY; SPECIES SPECIFICITY;

EID: 34247099621     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01618-06     Document Type: Article

References (29)

1. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46:245-247.
2. Bigley, V. H., R. F. Duarte, R. D. Gosling, C. C. Kibbler, S. Seaton, and M. Potter. 2004. Fusarium dimerum infection in a stem cell transplant recipient treated successfully with voriconazole. Bone Marrow Transplant. 34:815-817.
3. Capilla, J., M. Ortoneda, F. J. Pastor, and J. Guarro. 2001. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob. Agents Chemother. 45:2635-2637.
4. Consigny, S., N. Dhedin, A. Datry, S. Choquet, V. Leblond, and O. Chosidow. 2003. Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin. Infect. Dis. 37:311-313.
5. Cruse, M., R. Telerant, T. Gallagher, T. Lee, and J. W. Taylor. 2002. Cryptic species in Stachybotrys chartarum. Mycologia 94:814-822.
6. de Hoog, G. S., J. Guarro, J. Gené, and M. J. Figueras. 2000. Atlas of clinical fungi, 2nd ed. Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands.
7. Dignani, M. C., and E. J. Anaissie. 2004. Human fusariosis. Clin. Microbiol. Infect. 1:67-75.
8. Gilgado, F., J. Cano, J. Gené, and J. Guarro. 2005. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J. Clin. Microbiol. 43:4930-4942.
9. Guarro, J., and J. Gené. 1995. Opportunistic fusarial infections in humans. Eur. J. Clin. Microbiol. Infect. Dis. 14:741-754.
10. Guarro, J., I. Pujol, and E. Mayayo. 1999. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob. Agents Chemother. 43:1256-1257.
11. Hennequin, C., V. Lavarde, J. L. Poirot, M. Rabodonirina, A. Datry, S. Aractingi, J. Dupouy-Camet, D. Caillot, F. Grange, L. Kures, O. Morin, B. Lebeau, S. Bretagne, C. Guigen, D. Basset, and R. Grillot. 1997. Invasive Fusarium infections: a retrospective survey of 31 cases. J. Med. Vet. Mycol. 35:107-114.
12. Lewis, R. E., N. P. Wiederhold, and M. E. Klepser. 2005. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob. Agents Chemother. 49:945-951.
13. Mayayo, E., I. Pujol, and J. Guarro. 1999. Experimental pathogenicity of four opportunist Fusarium species in a murine model. J. Med. Microbiol. 48:363-366.
14. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
15. Nucci, M., E. J. Anaissie, F. Queiroz-Telles, C. A. Martins, P. Trabasso, C. Solza, C. Mangini, B. P. Simoes, A. L. Colombo, J. Vaz, C. E. Levy, S. Costa, V. A. Moreira, J. S. Oliveira, N. Paraguay, G. Duboc, J. C. Voltarelli, A. Maiolino, R. Pasquín, and C. A. Souza. 2003. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 98:315-319.
16. O'Donnell, K. 2000. Molecular phylogeny of the Nectria haematococca-Fusarium solani species complex. Mycologia 92:919-938.
17. O'Donnell, K., and E. Cigelnik. 1997. Two divergent intragenomic rADN ITS2 types within a monophyletic lineage of the fungus Fusarium are non-orthologous. Mol. Phylogenet. Evol. 7:103-116.
18. Ortoneda, M., J. Capilla, F. J. Pastor, I. Pujol, and J. Guarro. 2002. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob. Agents Chemother. 46:2273-2275.
19. Paphitou, N. I., L. Ostrosky-Zeichner, V. L. Paetznick, J. R. Rodriguez, E. Chen, and J. H. Rex. 2002. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob. Agents Chemother. 46:3298-3300.
20. Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. DuPont, J. de la Torre-Cisneros, G. Just-Nubling, H. T. Schlamm, I. Lutsar, A. Espinel-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
21. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and the Sentry Participants Group. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 46:1032-1037.
22. Pfaller, M. A., P. G. Pappas, and J. R. Wingard. 2006. Invasive fungal pathogens: current epidemiological trends. Clin. Infect. Dis. 43:3-14.
23. Pontón, J., R. Rüchel, K. V. Clemons, D. C. Coleman, R. Grillot, J. Guarro, D. Aldebert, P. Ambroise-Thomas, J. Cano, A. J. Carrillo-Muñoz, J. Gené, C. Pinel, D. A. Stevens, and D. J. Sullivan. 2000. Emerging pathogens. Med. Mycol. 38:225-236.
24. Pujol, I., J. Guarro, J. Gené, and J. Sala. 1997. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J. Antimicrob. Chemother. 39:163-167.
25. Raad, I. I., R. Y. Hachem, R. Herbrecht, J. R. Graybill, R. Hare, G. Corcoran, and D. P. Kontoyiannis. 2006. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42:1398-1403.
26. Sabatelli, F., R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNicholas. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015.
27. Swofford, D. L. 2001. PAUP*. Phylogenetic analysis using parsimony (*and other methods), version 4.0. Sinauer Associates, Sunderland, MA.
28. White, T. J., T. Bruns, S. Lee, and J. Taylor. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p. 315-322. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to the methods and applications. Academic Press, New York, NY.
29. Zhang, N., K. O'Donnell, D. A. Sutton, F. A. Nalim, R. C. Summerbell, A. A. Padhye, and D. M. Geiser. 2006. Members of the Fusarium solani species complex that cause infections in both humans and plants are common in the environment. J. Clin. Microbiol. 44:2186-2190.